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23.1 Introduction: Principles of biologics and their use as medicines.  
Between 2008 and 2010, 8 of the most costly 20 medications were biologics.  Biologics are 
medications that are produced by means of biological processes involving recombinant DNA 
(rDNA) technology.  rDNA is a form of artificial DNA that is created by combining two or 
more sequences that would not normally occur together through the process of DNA 
replication.  This is a very active area in medicine production. 
The decoding of the human genome revealed that there are 30,000 different genes encoding 
possibly 50,000 different proteins as a result of alternative gene splicing and posttranslational 
modification and that disease may result when one of these proteins is defective or present in 
abnormally high or low concentration. This ability to identify many of the causes of disease 
has presented a number of targets for possible therapies. Further, recombinant DNA 
technology has allowed a new generation of protein-based medicines, termed biologics, to be 
developed to take advantage of these new targets. Protein-based therapies have a number of 
advantages over conventional small-molecule drugs. Biologics often serve a highly specific 
and complex set of functions that cannot be mimicked by simple chemical compounds and 
there is less potential for protein-based drugs to interfere with normal biological processes 
and cause side effects. Further, since the body naturally produces many of the proteins that 
are used as therapies, biologics are often well tolerated and are less likely to elicit immune 
responses.  
Protein-based therapies come in three classes. Firstly, proteins, purified native or recombinant 
themselves are administered to remedy lesions resulting in disease; secondly, antibodies 
directed against important biochemical pathways have been developed and; thirdly new 
vaccines produced from molecules important in the disease process. 
23.2 Protein biologics used as drugs  
The use of biologics as therapies can be categorised in three ways: A protein that replaces one 
that is deficient or abnormal, a protein that augments an existing biological process or a 
protein that provides a novel function or activity.  
23.2.1 Proteins that function through enzymatic or regulatory activity.  
It is apparent that many pathophysiological states occur when a component, usually a protein 
or a metabolite occurring from the action of that protein, of a normal biological process is 
compromised in some way. Disease may occur when one of these proteins is defective or 
present in abnormally high or low concentrations. Thus supplementation with firstly proteins 
purified from animal sources and, now, with recombinant human protein homologues allows 
for new therapeutic targets in the treatment of these diseases.  
Treatment of type I diabetes mellitus with exogenous insulin is perhaps the best and most 
illustrative example of how a protein has come to be used therapeutically. Diabetes mellitus 
results from an inability to sequester glucose from the blood. Diabetes mellitus occurs when 
circulating insulin levels decline or when the target cells become resistant to the hormone. As 
well as carbohydrates, insulin has a profound effect on the metabolism and utilisation of 
lipids and fats. Insulin was first isolated from porcine and bovine pancreas in 1922 and was 
used therapeutically almost immediately as a lifesaving daily injection. However two 
problems associated with their use became quickly apparent; firstly an immune reaction to 
the animal proteins and secondly, purifying it from animal sources is expensive and time 
consuming. For example, in 1923, Harold Ward Dudley published a purification scheme 
where he was able to purify 74g of insulin from 104kg of pancreas tissue using a procedure 
that took about 3 days.  
Once the human gene for insulin was isolated, it became a prime target for recombinant 
DNA technology. This has resulted in the production of large amounts of human insulin that 
is inexpensive, of low immunogenicity and free from other animal pancreatic substances. 
Indeed recombinant human insulin was approved in the United States in 1982 and was the 
first commercially available recombinant protein drug. More recently, “genetic tinkering” has 
allowed the production of new insulin types with altered properties such as quicker onset and 
longer duration of action. The use of recombinant insulin in the treatment of type I diabetes is 
discussed in Chapter 15. 
However, great success has also been achieved using purified protein preparations from 
animal and microbial sources. For example in cystic fibrosis, defects in the chloride channel 
can result in abnormally thick secretions that can block pancreatic enzymes from travelling 
down the pancreatic duct to the duodenum preventing food being properly digested resulting 
in patient malnutrition. Patients can be treated with a combination of porcine pancreatic 
enzymes (Pancrease) purified from pigs to aid digestion.  
Similarly, lactose intolerance is the condition in which lactase, an enzyme needed for proper 
metabolism of lactose (a constituent of milk and other dairy products), is not produced in 
adulthood. The management of lactose intolerance includes preparing foods (Digestelact) in 
which the lactose content is decreased by treating with lactase from the food yeast 
Saccharomyces Sp. 
23.2.1.1 Biologics as replacement of a deficient or abnormal protein.  
Insulin has been previously indicated as the prototypical biologic medicine. Treatment by 
addition of exogenous insulin is the preferred treatment for type I diabetes and is used 
extensively in type II diabetes. However, other conditions characterised by deficiencies are 
treated in a similar manner.  
Deficiencies in various coagulation factors typify a number of inherited bleeding disorders.  
Clotting factor VIII deficiency manifests itself in haemophilia A whilst lack of factor IX 
results in haemophilia B. Treatment for both of these conditions is by supplementation of the 
missing proteins using either purified blood products or, more commonly, human 
recombinant proteins. The development and use of recombinant clotting factors in 
conjunction with better screening methods has drastically reduced the incidence of infection 
of haemophiliacs with HIV.  
Growth failure caused by growth hormone (somatotropin) deficiency or as symptoms from 
pathological states such as Prader-Willi disease or Turners syndrome can be treated by 
exogenous administration of recombinant human growth hormone produced either in E. 
coli (Genotropin) or from genetically engineered mammalian cells (Saizen).  
Gaucher’s disease is a lysosomal storage disease caused by a deficiency in the enzyme β-
glucocerebrosidase which hydrolyses glucocerebroside to glucose and ceramide. Deficiency 
in this enzyme results in an accumulation of the substrate in a variety of tissues including 
spleen, liver, kidneys, lungs, brain and bone marrow. Types I and III, the adult forms of the 
disease can be treated by replacement treatment with recombinant β-glucocerebrosidase 
(Imiglucerase), which, when given intravenously every two weeks, can dramatically 
decrease liver and spleen size, reduce skeletal abnormalities, and reverse other 
manifestations.  
23.2.1.2 Proteins that augment an existing biological process.  
Infertility is an example of a biological process that can treated by augmentation with key 
regulatory molecules. Recombinant human chorionic gonadotrophin hormone (Ovidrel) is 
produced from genetically modified Chinese hamster ovary cells and used in women 
undergoing superovulation prior to assisted reproductive techniques such as in vitro 
fertilisation (IVF). Ovidrel is administered to trigger final follicular maturation and 
luteinisation after stimulation of follicular growth. In addition, Ovidrel is administered to 
trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation 
of follicular growth.  
Human recombinant CSF (Leukine) stimulates proliferation and differentiation of 
neutrophils, eosinophils & monocytes in patients with leukopaenia and HIV.  
Furthermore, it should also be noted that a family of human recombinant interferons have 
been produced for use in a number of conditions such as hepatitis C (Infergen), hepatitis B 
(Intron A) and multiple sclerosis (Betaferon) where they have an undefined but probable 
immunomodulatory effect.  
Lastly the active fragment (1-34) of recombinant human parathyroid hormone 
(Teriparatide) is used to treat osteoporosis by activating osteoblasts and stimulating the 
formation of new bone. 
23.2.1.3 Proteins that provide a novel function or activity.  
 
Erythropoietin (EPO) is probably best known for its use as a performance-enhancing drug 
used by cyclists to increase their red blood cells.  With increased red blood cells, which carry 
oxygen, the cyclist has increased stamina in endurance events. 
 
Physiologically, EPO is an endogenous glycoprotein produced by the kidney, and has a major 
role in promoting red blood cell survival and producing the precursors of red blood cells.  
Erythropoietin is an endogenous glycoprotein that stimulates red blood cell production. 
Recombinant DNA technology has allowed for the production of human erythropoietin 
homologues that vary in their carbohydrate groups but that are indistinguishable from human 
erythropoietin in biological activity and immunological reactivity. These include epoetin alfa 
(Procrit) and darbepoetin alfa (Aranesp) that are purified from Chinese hamster ovary cells 
into which the gene coding for human erythropoietin has been inserted. These drugs are 
indicated for the treatment of anaemia associated with chronic renal failure (CRF) and for 
other condition where there is a reduced number of red blood cells e.g. as a result of the 
treatment of cancer. 
 
Similarly, tenecteplase (Metalyse) is a tissue plasminogen activator (tPA) produced by 
recombinant DNA technology that binds to the fibrin component of the thrombus (blood clot) 
and converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of 
the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to 
inactivation by its endogenous inhibitor compared to native tPA. Metalyse is indicated for 
the thrombolytic treatment of the acute phase of myocardial infarction. 
 
23.2.1.3 Proteins that provide a novel function or activity.  
Introduction of a foreign substance (an antigen) into a vertebrate such as a mouse or a human 
has a profound effect on the body’s defence mechanism, the immune system. One response to 
such an exposure is that some of the immune system's B-cells will turn into plasma cells and 
start to produce antibodies (immunoglobulins) that bind to that antigen. Indeed the word 
antigen is derived from the term antibody generator. Although each activated B-cell is only 
capable of producing one kind of antibody, antigen exposure results in the activation of 
different B-cells that each produce structurally different antibodies that bind to different parts 
(epitopes) of the antigen. This natural mixture of antibodies is known as polyclonal 
antibodies. These circulating antibodies protect their host by binding to and neutralising 
foreign proteins (e.g. toxins) resulting in negation of their deleterious effects. 
23.2.2. Proteins that function through specific targeting activity.  
Although the use of antibodies as therapies for a variety of pathologies has been postulated 
for over one hundred years, a number problems associated with their use were observed. In 
particular, variability caused by their polyclonal nature and adverse immunological side 
effects had blunted their effectiveness as therapeutic agents. However, the development of 
monoclonal antibodies, in which a myeloma cell line that has lost its ability to secrete 
antibodies is fused with healthy antibody secreting B-cells, coupled with the ability to modify 
their immunogenicity by protein engineering or “humanising” them has revolutionised their 
use. The resultant immortalised fused cells (hybridomas) are able to continuously secrete 
industrial quantities of highly specific, single epitope antibodies for use in a number of 
diseases particularly cancer and autoimmune diseases. In 1986, Muromonab-CD3, used to 
combat tissue rejection in renal transplantation was the first monoclonal antibody approved 
by the FDA. To date, some 150 monoclonal antibodies are used to treat disease.  
23.2.2.1. Monoclonal antibody nomenclature.  
The suffix ending on the name of a monoclonal antibody gives an indication into the nature 
of the molecule. Original monoclonal antibodies were derived from mouse tissues and have 
an -omab suffix (for example Ibrutumomab tiuexetan) whereas chimeric monoclonal 
antibodies, which have an -ximab suffix (infliximab) are derived from mouse antibodies with 
human sequences inserted to reduce immunogenicity. Humanised monoclonal antibodies, in 
which human antibodies have mouse domains grafted onto them, have a –zumab suffix 
(trastuzumab) whilst unmodified human monoclonal antibodies have an –umab ending 
(adalimumab). 
23.2.2.2. Naked monoclonal antibodies.  
Naked monoclonal antibodies are those that have no cytotoxic chemicals or radionuclides 
attached to them. They work by either specifically marking the target cell for the immune 
system to destroy it or attach to cell surface receptors blocking binding of various molecules 
known to enhance cell growth or proliferation.  This group encompasses the vast majority of 
therapeutic antibodies. Naked monoclonal antibodies have been shown to be particularly 
effective in the treatment of cancer, autoimmune disease and cardiac disease. An extensive 
analysis of current use of these antibodies is outwith the remit of this chapter, however, some 
of the more common treatments are as follows.  
Infliximab (Remicade) is a chimeric human-murine monoclonal antibody that binds to 
human tumour necrosis factor alpha (TNFα). TNFα is a pro-inflammatory and 
immunoregulatory cytokine that, when overexpressed, mediates chronic inflammation in 
diseases such as Crohn’s disease and rheumatoid arthritis. Infliximab neutralises the 
biological activity of TNFα by binding with high affinity to the soluble and transmembrane 
forms of TNFα and inhibits binding of TNFα with its receptors.  
Alemtuzumab (MABCampath) is a genetically engineered humanised monoclonal antibody 
specific for a lymphocyte cell surface glycoprotein, (CD52) antigen. Alemtuzumab causes 
the lysis of lymphocytes by binding to CD52 antigen, which is expressed on the surface of all 
B and T lymphocytes (benign and cancerous). As such, alemtuzumab is indicated for the 
treatment of patients with relapsed B-cell chronic lymphocytic leukaemia (CLL). 
Abciximab (ReoPro) is an antibody that binds to the intact platelet GPIIb/IIIa receptor, 
which is the major platelet surface receptor involved in platelet aggregation. Abciximab 
inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor 
and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. Abciximab is 
indicated for percutaneous coronary intervention, the prevention of ischaemic cardiac 
complications in patients undergoing percutaneous coronary intervention (PCI) (balloon 
angioplasty, atherectomy and stent placement). In patients with unstable angina refractory to 
conventional treatment, where PCI is planned, it may be used 18 to 24 hours prior to the 
planned intervention.  
Trastuzumab (Herceptin) is a recombinant humanised monoclonal antibody that selectively 
targets the extracellular domain of the human epidermal growth factor receptor 2 protein 
(HER2), a protein which is overexpressed in 25%-30% of primary breast cancers. These 
tumours are particularly aggressive and deliver a shortened disease-free survival compared to 
patients whose tumours do not overexpress HER2. Herceptin is indicated for the treatment of 
patients with HER2 positive localised breast cancer in association with chemotherapy. 
Rituximab (MabThera), is a chimeric monoclonal antibody directed against the CD20 
protein, that destroys both normal and malignant B cells that have CD20 on their surfaces. It 
is indicated for non-Hodgkin lymphoma and chronic lymphocytic leukaemia. 
Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody directed against 
the interleukin-2 (IL-2) receptor found in  T cells and  is used to prevent rejection in organ 
transplantation, especially in kidney transplants.  It acts as an antagonist at the interleukin-2 
binding site of the high affinity IL-2 receptor on the surface of the activated T lymphocytes. 
23.2.2.3. Conjugated monoclonal antibodies.  
Conjugated monoclonal antibodies are those antibodies that are joined to drugs, toxins or 
radionuclides. The antibodies are used as delivery vehicles taking those cytotoxins directly to 
the target cells. Although fewer in number at present than their naked counterparts, it is 
expected that the number of conjugated antibodies will increase in the coming years. 
Conjugates include ozogamycin which is a calicheamicin antibiotic, mafenatox which is an 
enterotoxin isolated from staphylococcus aureus and mertansine, which is a macrolide found 
in the staff vine plant. All of these conjugates have been demonstrated to be excellent 
cytotoxins, particularly useful in the killing of cancer cells.  
Of the two immunotoxin thus far to receive FDA approval for treating cancer, gentuzumab 
ozogamycin (Mylotarg) which contains calicheamicin was used to treat acute myelogenous 
leukaemia (AML).  It was withdrawn from market in 2010 when clinical trials demonstrated 
that the drug increased patient death and added no benefit over conventional cancer therapies.  
The second immunotoxin, brentuximab vedotin, indicated for treat treatment of anaplastic 
large cell lymphoma (ALCL) and Hodgkin lymphoma was approved by the FDA in 2011. 
Other immunotoxins are in various stages of clinical trials including trastuzumab emtansine 
which shows promise for the treatment of HER2 positive breast cancers and it is expected 
that other immunotoxins will be approved in the coming years. 
Radioimmunotherapy uses monoclonal antibodies tagged with a radionuclide to deliver 
cytotoxic radiation to the target cell. In 2003, the FDA approved ibritumomab tiuexetan 
(Zevalin) which is tagged with Yttrium-90 (
90
Y) for use as a treatment for non-Hodgkin 
lymphoma. The following year, it approved Iodine (
131
I) tositumomab (Bexxar) as 
treatment for the same disease. 
23.2.3. Recombinant protein vaccines.  
Whereas addition of exogenous antibody can be seen to provide passive immunity against a 
pathological condition, a vaccine is an antigenic preparation that produces an active 
immunity to a disease such as to prevent or ameliorate the effects of infection by any natural 
or wild strain of the causative organism. Vaccines have been used in one form or another for 
over 200 years when Edward Jenner, using inoculation with cowpox virus demonstrated 
protection against the deadlier smallpox virus.  
Vaccines may be obtained from living, weakened strains of the pathogens (bacteria or virus) 
which intentionally give rise to trivial infections or they may be obtained from killed or 
inactivated (attenuated) pathogens or purified products derived from them.  
Increasingly, however, a new generation of vaccines derived from appropriate immunogenic 
(but non-pathogenic) protein components of a micro-organism produced through recombinant 
DNA technology, has shown that vaccines can be created that provide immunity in an 
individual without exposure of that individual to the risks of infection. Such recombinant 
protein vaccines are proving invaluable in the treatment of infection, autoimmune diseases 
and cancer. For example, a new hepatitis B vaccine was created by from the production of a 
recombinant HBsAg protein, a non-infectious protein of the Hepatitis B virus. Similarly, two 
vaccines, the quadrivalent Gardasil and the bivalent Cervarix have been developed to 
combat human papillomavirus (HPV) infection, the causative agent that is responsible for 
70% of precancerous lesions that can develop into cervical cancer. These vaccines were 
developed from recombinant viral coat proteins and are designed as preventative (rather than 
therapeutic) vaccines, recommended for women who are 9 to 25 years old and have not 
contracted HPV.  
 
